Biotherapeutics

Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement

Broad-based alliance to develop products for a wide range of animal species PLEASANTON, Calif., March 4 /PRNewswire/ -- The Animal Health Division of Bayer HealthCare AG and Juvaris BioTherapeutics, Inc. jointly announced today that the companies have executed a broad-based licensing agreement. ...

Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford

Unrestricted Educational Grant Supports Diagnosis and Patient Access to Care STANFORD, Calif., March 3 /PRNewswire/ -- The Jeffrey Modell Foundation (JMF) and Talecris Biotherapeutics, Inc. have donated $150,000 to Lucile Packard Children's Hospital at Stanford...

Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors

CARMIEL, Israel, Feb. 12 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), announced today that Professor Roger D. Kornberg, renowned Biochemist and laureate of the Nobel Prize in Chemistry, has been appointed to the Company's board of directors. Professor Kornberg is a...

Protalix BioTherapeutics Announces Resignation of Board Members

CARMIEL, Israel, Dec. 5 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), announced today that two of its directors, Phillip Frost, M.D. and Jane H. Hsiao, Ph.D., have resigned from the Company's Board of Directors, effective immediately. Both resigned for personal reason...

Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment

CARMIEL, Israel, Sept. 28 /PRNewswire-FirstCall/ -- The Russell Investment Group has advised Protalix Biotherapeutics (Amex: PLX ) that there will be a float weight adjustment effective after the close of trading on September 28, 2007 in the following indexes: Russell 2000, Russell 2000 Growt...

Professor Bruce Beutler Joins aTyr Pharma's Scientific Advisory Board

...R), the prototype for the most successful class of biotherapeutics ever developed: recombinant inhibitors of TNF that...ize on his experience to develop these proteins as biotherapeutics for treatment of inflammatory diseases as quickly ... biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA s...

aTyr Pharma Raises an Additional $12 Million

...as raised an additional $12 million to fund its discovery operations and development of its lead candidate. The company is discovering and developing biotherapeutics to treat a wide variety of diseases, including inflammation, autoimmune, hematopoietic and metabolic disorders. Founded in 2006 by Paul Schimmel, a P...

Oxygen Biotherapeutics, Inc. Announces Closing of Offer to Acquire Warrants

...ith the Securities and Exchange Commission, which are available on the SEC website at www.sec.gov and through our website at www.oxybiomed.com. Oxygen biotherapeutics disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe har...

FDA Accepts Final Section of NDA Filing for LUCASSIN(R)

...LUCASSIN (R) (terlipressin), for the treatment of hepatorenal syndrome (HRS) Type 1. About Ikaria Holdings, Inc. Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company's lead product, INOmax(R) ...

Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results

...d to $204,069 as of April 30, 2009, as compared to $4.6 million as at October 31, 2008. About Haemacure Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by it...

Biotherapeutics in Medical Technology

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

OXFORD, England, May 18 /PRNewswire/ -- - New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of Therapeutic Antibodies Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic an...

Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study

CARMIEL, Israel, Jan. 22 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), today announced that it has achieved proof of concept results in an animal study conducted as part of its Acetylcholinesterase (AChE) Program. The Acetylcholinesterase (AChE) Program is being condu...

Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention

Collaboration with CDC to Focus on Testing of Juvaris JVRS-100 as an Adjuvant with existing H5N1 vaccine for dose-sparing and cross protection PLEASANTON, Calif., Jan. 15 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today that The Centers for Disease Control and Prevention and Ju...

Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania

First Patients Enrolled and Being Treated BETHESDA, Md., Dec. 27 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO) (AIM: NWBT; NWBS) ("NWBT") today announced that a Phase I/II clinical trial in at least 30 patients, using DCVax(R)-L for recurre...

Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD

First patient treated in trial of prGCD treatment of Gaucher Disease CARMIEL, Israel, Aug. 27 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), today announced that it has treated the first patient in its phase III clinical trial of the Company's lead product candidate,...

GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled to present on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E. Unterberg, Towbin Emerging Growth Life Opportunities C...

Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications

... aTyr Pharma Targets for Novel biotherapeutics Based On Naturally Resected tRNA Synthetases SAN DIEGO, June 29 /PRNewswire/ -- Pangu BioPharma, a subsidiary of aTyr Pharma in Hong Kong, today...

Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research

... the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Hospital Res...

CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency

...usea and vomiting. For more information, visit www.riastap.com . About CSL Behring CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived...

CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial

...s seven sites that are open for enrollment and intends to announce additional sites as they open for screening patents. About Car d ioVascular biotherapeutics CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a ti...

Biotherapeutics in Biological News

Previous claims of siRNA therapeutic effects called into question by report in human gene therapy

...b.com/hum Marjorie Robbins, Adam Judge, Ellen Ambegia, Catherine Choi, Ed Yaworski, Lorne Palmer, Kevin McClintock, and Ian MacLachaln of Protiva biotherapeutics (Burnaby, BC Canada), in a paper entitled, "Misinterpreting the Therapeutic Effects of siRNA Caused by Immune Stimulation," emphasize the need for res...

Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants

... 28 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced today that the U.S. Food and Drug Administration (FDA) h... About Ikaria Holdings, Inc. Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative phar...

Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants

... 28 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced today that the U.S. Food and Drug Administration (FDA) h... About Ikaria Holdings, Inc. Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative phar...

Data published in PNAS show antibodies can be made 10 times more toxic to cancer cells

...n therapeutic success, and many development-stage antibodies fail in clinical trials due to lack of demonstrated efficacy. Scientists at Xencor, a biotherapeutics company developing protein and antibody therapeutics, said the changes it made to the antibody Fc regions increased antibody effector functions such a...

Biotherapeutics in Biological Technology

Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.

BETHESDA, Md., July 23 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) today announces that it will seek shareholder approval for the Company to cancel its listing on the London Stock Exchange's AIM market ("AIM") (the "De-lis...

CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement

MELBOURNE, Australia and RESEARCH TRIANGLE PARK, N.C., June 8 /PRNewswire/ -- CSL Limited (ASX: CSL) and Talecris Biotherapeutics, Inc. announced today that they have mutually agreed to terminate their merger agreement, announced on August 12, 2008, under which CSL agreed to acquire Talecris for U...

Northwest Biotherapeutics Secures $700,000 Equity Financing

BETHESDA, Md., Feb. 10 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC Bulletin Board: NWBO) (the "Company") announces today receipt of $700,000 in cash from Al Rajhi Holdings through the subscription of 1,000,000 new shares in the form of the Company's commo...

Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action

BETHESDA, Md., Jan. 8 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBS and NWBT) (the "Company" or "NWBT") announced today settlement of a putative securities class action lawsuit, In re Northwest Biotherapeutics, Inc. Securities Litigation , No. C-...

Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses

Vaccine Has Potential to Save Millions of Lives GERMANTOWN, Md., Oct. 7 /PRNewswire/ -- Integrated BioTherapeutics Inc. (IBT), a biotechnology company focused on development of medical countermeasures for biodefense and emerging infectious diseases, announced they have been awarded...

Northwest Biotherapeutics to Present at Next Generation Vaccine Conference

Highlights Include Clinical Trial Updates BETHESDA, Md., July 18 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC Bulletin Board: NWBO), (the "Company or NWBT"), today announced that Dr. Alton L. Boynton, its President and Chief Executive Office...

Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel

CARMIEL, Israel, Jan. 14 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), announced today that it has signed a lease agreement for the expansion of its manufacturing and research facility. The expanded space, located in the Company's facility in Carmiel, Israel, will pro...

Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders

CARMIEL, Israel, Nov. 29 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), today announced that its board of directors has set the close of business on December 24, 2007, as the record date for shareholders entitled to receive notice of, and to vote at, the Company's 2007...

Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference

CARMIEL, Israel, Nov. 2 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), today announced that Dr. David Aviezer, Ph.D., its President and Chief Executive Officer, will present at the CIBC World Markets 18th Annual Healthcare Conference. Dr. Aviezer's presentation will ta...

Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock

CARMIEL, Israel, Oct. 24 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share. The Company has granted a 30-day option to the...